August 26, 2009 (FinancialWire) — Anna E. Gluskin, the chairman, president and CEO of Generex Biotechnology Corp. (NASDAQ: GNBT) (www.generex.com), was featured recently on “Market News” on Canada’s Business News Network to discuss the current circumstances of H1N1 and how Generex’s synthetic vaccine platform can respond to the swine flu’s ever-changing DNA.

The segment can be viewed online at http://watch.bnn.ca/clip206593#clip206594 and will be available later at www.generex.com.

Interviewed by program host Pat Bolland, Gluskin explained how the company’s synthetic vaccines differ from traditional egg-based vaccines. While traditional egg-based vaccines take months to develop and rely on live virus — which always carries the risk of infecting rather than inoculating — Generex’s synthetic vaccine platform does not use live virus. Instead, peptides are arranged to create a “snapshot” of the virus activate the body’s T-cells to fight off the foreign invader, completely eliminating any risk of infection and resulting in potentially more effective vaccines that can be produced much more quickly and at approximately 1/10th the cost of egg-based vaccines. The more than 182,000 cases of swine flu already reported to WHO this year underline the importance of being able to quickly produce mass quantities of an effective vaccine as inexpensively as possible.

Generex’s vaccine platform is already in various stage clinical trials for avian flu, as well as prostate, breast and ovarian cancers, melanomas, SARS and HIV/AIDS.

In addition to the company’s vaccine platform technology, Generex has developed a range of products based on their proprietary RapidMist(tm) platform technology for drug delivery through the inner lining of the mouth, ensuring that there is no deposit in the lungs. The company’s flagship product, Generex Oral-lyn(tm) is an oral insulin spray product for the treatment of Type-1 and Type-2 diabetes, available to patients in certain overseas markets and in Phase III global clinical trials.

Generex has also developed and markets Glucose RapidSpray(tm), an over-the-counter product designed for use early in the onset of a low blood sugar episode; BaBOOM!(tm) Energy Spray, a convenient and great-tasting energy spray alternative to energy drinks; and Crave-NX(tm) 7-Day Diet Aid Spray, clinically tested and designed to quickly curb cravings throughout the day. The company is also developing MetControl(tm), a chewing gum form of the common generic Metformin pill.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.